Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Clin Transl Oncol. 2018 May 7;20(11):1474–1483. doi: 10.1007/s12094-018-1888-2

Figure 2.

Figure 2

Figure 2

Figure 2

Change in Tumor-Based Markers between MK-2206-treated patients and Untreated Controls. The vertical bar represents the protein expression change by immunohistochemistry (IHC) from surgical excision tissue to core biopsy in each treated patient. There was no difference observed in ki-67 (A), pAKT (B) PTEN (C), pS6 (D), and stathmin (E). Untreated control patients are illustrated (left) and MK-2206-treated patients (right) by dose. Mutations in the PI3K/AKT pathway are identified by asterix (*AKT mutation; ** PIK3CA mutation; ***PTEN mutation).